GlycoMimetics (GLYC) Competitors $0.33 -0.05 (-13.16%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends GLYC vs. BLUE, ME, CASI, PMVP, IKNA, ONCY, QNCX, IMAB, CLSD, and CMRXShould you be buying GlycoMimetics stock or one of its competitors? The main competitors of GlycoMimetics include bluebird bio (BLUE), 23andMe (ME), CASI Pharmaceuticals (CASI), PMV Pharmaceuticals (PMVP), Ikena Oncology (IKNA), Oncolytics Biotech (ONCY), Quince Therapeutics (QNCX), I-Mab (IMAB), Clearside Biomedical (CLSD), and Chimerix (CMRX). These companies are all part of the "medical" sector. GlycoMimetics vs. bluebird bio 23andMe CASI Pharmaceuticals PMV Pharmaceuticals Ikena Oncology Oncolytics Biotech Quince Therapeutics I-Mab Clearside Biomedical Chimerix GlycoMimetics (NASDAQ:GLYC) and bluebird bio (NASDAQ:BLUE) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends. Does the MarketBeat Community favor GLYC or BLUE? bluebird bio received 724 more outperform votes than GlycoMimetics when rated by MarketBeat users. Likewise, 71.16% of users gave bluebird bio an outperform vote while only 59.89% of users gave GlycoMimetics an outperform vote. CompanyUnderperformOutperformGlycoMimeticsOutperform Votes31559.89% Underperform Votes21140.11% bluebird bioOutperform Votes103971.16% Underperform Votes42128.84% Is GLYC or BLUE more profitable? GlycoMimetics has a net margin of 0.00% compared to bluebird bio's net margin of -565.74%. GlycoMimetics' return on equity of -160.93% beat bluebird bio's return on equity.Company Net Margins Return on Equity Return on Assets GlycoMimeticsN/A -160.93% -132.85% bluebird bio -565.74%-322.46%-53.17% Do analysts prefer GLYC or BLUE? GlycoMimetics currently has a consensus price target of $10.00, suggesting a potential upside of 2,930.30%. bluebird bio has a consensus price target of $3.03, suggesting a potential upside of 898.35%. Given GlycoMimetics' higher probable upside, equities analysts plainly believe GlycoMimetics is more favorable than bluebird bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GlycoMimetics 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00bluebird bio 2 Sell rating(s) 7 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media favor GLYC or BLUE? In the previous week, bluebird bio had 22 more articles in the media than GlycoMimetics. MarketBeat recorded 22 mentions for bluebird bio and 0 mentions for GlycoMimetics. GlycoMimetics' average media sentiment score of 0.00 beat bluebird bio's score of -0.07 indicating that GlycoMimetics is being referred to more favorably in the media. Company Overall Sentiment GlycoMimetics Neutral bluebird bio Neutral Do institutionals & insiders hold more shares of GLYC or BLUE? 75.2% of GlycoMimetics shares are owned by institutional investors. Comparatively, 87.4% of bluebird bio shares are owned by institutional investors. 8.7% of GlycoMimetics shares are owned by insiders. Comparatively, 1.4% of bluebird bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has better earnings and valuation, GLYC or BLUE? GlycoMimetics has higher earnings, but lower revenue than bluebird bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGlycoMimetics$10K2,127.84-$36.90MN/AN/Abluebird bio$29.50M2.00-$211.91M-$1.87-0.16 Which has more volatility & risk, GLYC or BLUE? GlycoMimetics has a beta of 1.85, indicating that its stock price is 85% more volatile than the S&P 500. Comparatively, bluebird bio has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500. SummaryGlycoMimetics beats bluebird bio on 8 of the 15 factors compared between the two stocks. Ad Crypto 101 MediaBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Get GlycoMimetics News Delivered to You Automatically Sign up to receive the latest news and ratings for GLYC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLYC vs. The Competition Export to ExcelMetricGlycoMimeticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$21.28M$6.44B$5.06B$8.82BDividend YieldN/A8.11%5.18%4.07%P/E RatioN/A10.78126.3217.81Price / Sales2,127.84243.711,179.2574.56Price / CashN/A22.1633.8632.53Price / Book0.555.474.684.68Net Income-$36.90M$153.61M$119.54M$226.08M7 Day Performance-17.38%-2.00%-1.83%-1.04%1 Month Performance106.25%-7.46%-3.60%1.04%1 Year Performance-78.00%31.82%31.91%26.28% GlycoMimetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLYCGlycoMimetics3.6737 of 5 stars$0.33-13.2%$10.00+2,930.3%-78.4%$21.28M$10,000.000.0050Gap DownBLUEbluebird bio2.8596 of 5 stars$0.30flat$3.03+898.3%-92.1%$58.92M$29.50M-0.17323Analyst ForecastME23andMe1.1142 of 5 stars$3.15-8.2%$9.40+198.4%-82.6%$84.08M$219.64M0.00770CASICASI Pharmaceuticals3.7991 of 5 stars$5.22-2.2%$6.00+14.9%+0.4%$82.56M$22.06M-2.34180PMVPPMV Pharmaceuticals2.804 of 5 stars$1.57-1.3%$5.80+269.4%-36.9%$82.28MN/A0.0050IKNAIkena Oncology3.4984 of 5 stars$1.70+1.2%$3.00+76.5%-0.6%$82.04M$659,000.00-1.3870ONCYOncolytics Biotech1.2173 of 5 stars$1.00-5.7%$4.00+300.6%-37.2%$81.70MN/A0.0030Analyst RevisionQNCXQuince Therapeutics2.8745 of 5 stars$1.84+4.0%$8.50+362.0%+109.1%$80.96MN/A-1.4860IMABI-Mab2.5456 of 5 stars$0.98+3.2%$8.00+716.3%-37.6%$79.80M$3.89M0.0034Gap UpCLSDClearside Biomedical3.0244 of 5 stars$1.05+1.9%$5.33+407.9%+8.1%$79.63M$8.23M-2.2930Analyst RevisionCMRXChimerix4.5147 of 5 stars$0.88flat$8.50+865.9%-12.0%$79.15M$320,000.00-0.9472Analyst Forecast Related Companies and Tools Related Companies bluebird bio Alternatives 23andMe Alternatives CASI Pharmaceuticals Alternatives PMV Pharmaceuticals Alternatives Ikena Oncology Alternatives Oncolytics Biotech Alternatives Quince Therapeutics Alternatives I-Mab Alternatives Clearside Biomedical Alternatives Chimerix Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GLYC) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GlycoMimetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GlycoMimetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
